Gewinn- und Verlustrechnung von Emergent BioSolutions Inc.

Emergent BioSolutions shares sold off after the Company posted roughly $234 million in quarterly revenue -- above its own prior guidance -- while also recording a $191.3 million NARCAN impairment. Levi & Korsinsky is investigating potential securities law violations. Emergent BioSolutions shares sold off after the Company posted roughly $234 million in quarterly revenue -- above its own prior guidance -- while also recording a $191.3 million NARCAN impairment. Levi & Korsinsky is investigating potential securities law violations.

Emergent BioSolutions (NYSE: EBS) shareholders took losses after the Company disclosed a $191.3 million non-cash impairment on its NARCAN franchise, attributed

NEW YORK--(BUSINESS WIRE)--Emergent BioSolutions (NYSE: EBS) shareholders took losses after the Company disclosed a $191.3 million non-cash impairment on its NARCAN franchise, attributed to increased competition and pricing pressure in naloxone. If you suffered a loss on your Emergent BioSolutions investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. NARCAN Nasal.

Emergent BioSolutions cut its FY2026 adjusted EBITDA outlook to $130-$150 million from $155-$175 million  amid continued NARCAN pricing and margin pressure, with NARCAN gross margin having fallen to 16% in Q1 2026. SueWallSt notifies investors of a pending investigation into potential securities law violations.

Emergent BioSolutions cut FY2026 revenue guidance to $645-$675 million after reaffirming a $720-$760 million outlook three months earlier. Levi & Korsinsky is investigating potential securities law violations.

Emergent Biosolutions NYSE: EBS reported second-quarter 2026 revenue and adjusted EBITDA above its prior guidance and analyst consensus, driven by accelerated medical countermeasure deliveries to U.S. government customers. The company also lowered its full-year outlook as increased competition and pricing pressure in the naloxone market are expected to weigh on sales of NARCAN.

Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript

GAITHERSBURG, Md. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents.

Second Quarter 2026 Total Revenues of $234. 3 million, an improvement of 66% versus prior year Second Quarter 2026 Net Loss of $180. 2 million worsening 1,402% versus prior year, largely due to a $191. 3 million non-cash impairment charge Second Quarter 2026 Adjusted Net Income of $30.

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological incidents, whether naturally occurring outbreaks, accidental releases or deliberate acts, which represent a critical component of national resilience and security planning.